RAPP
Rapport Therapeutics Inc (RAPP)
Healthcare • NASDAQ • $38.04-4.73%
- Symbol
- RAPP
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $38.04
- Daily Change
- -4.73%
- Market Cap
- $1.82B
- Trailing P/E
- N/A
- Forward P/E
- -8.87
- 52W High
- $42.27
- 52W Low
- $7.73
- Analyst Target
- $54.20
- Dividend Yield
- N/A
- Beta
- N/A
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience Ne…
Company websiteResearch RAPP on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.